CN111163782A - 治疗射血分数保留型心力衰竭的方法 - Google Patents

治疗射血分数保留型心力衰竭的方法 Download PDF

Info

Publication number
CN111163782A
CN111163782A CN201880063705.4A CN201880063705A CN111163782A CN 111163782 A CN111163782 A CN 111163782A CN 201880063705 A CN201880063705 A CN 201880063705A CN 111163782 A CN111163782 A CN 111163782A
Authority
CN
China
Prior art keywords
patient
day
hfpef
administered
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880063705.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿拉库-博泽克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of CN111163782A publication Critical patent/CN111163782A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880063705.4A 2017-10-02 2018-10-02 治疗射血分数保留型心力衰竭的方法 Pending CN111163782A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566668P 2017-10-02 2017-10-02
US62/566,668 2017-10-02
PCT/IB2018/057648 WO2019069230A1 (en) 2017-10-02 2018-10-02 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION

Publications (1)

Publication Number Publication Date
CN111163782A true CN111163782A (zh) 2020-05-15

Family

ID=63963334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063705.4A Pending CN111163782A (zh) 2017-10-02 2018-10-02 治疗射血分数保留型心力衰竭的方法

Country Status (12)

Country Link
US (1) US11617754B2 (https=)
EP (1) EP3691650A1 (https=)
JP (1) JP2020536121A (https=)
KR (1) KR20200102982A (https=)
CN (1) CN111163782A (https=)
BR (1) BR112020006472A2 (https=)
CA (1) CA3078163A1 (https=)
IL (1) IL273723A (https=)
MX (1) MX2020003243A (https=)
TW (1) TW201924689A (https=)
WO (1) WO2019069230A1 (https=)
ZA (1) ZA202002292B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115770062A (zh) * 2021-09-07 2023-03-10 深圳迈瑞生物医疗电子股份有限公司 一种超声波数据的处理方法、成像装置
CN116440075A (zh) * 2023-06-01 2023-07-18 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006984A1 (fr) * 2009-07-17 2011-01-20 Poxel Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
US20150246045A1 (en) * 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
US20170266152A1 (en) * 2016-03-16 2017-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
KR101618198B1 (ko) 2008-05-23 2016-05-04 뽁셀 에스아에스 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
BRPI0916197B1 (pt) 2008-07-29 2018-01-23 Poxel Processo para isolar componentes enantioméricos de uma mistura de enantiômeros
TW201033182A (en) 2008-12-12 2010-09-16 Poxel Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
US8592370B2 (en) 2008-12-12 2013-11-26 Poxel S.A.S. Combination of insulin with triazine derivatives
JP5536869B2 (ja) 2009-03-26 2014-07-02 ポクセル・エスアーエス 優先晶出法を利用したジヒドロ−１，３，５トリアジンラセミ体のエナンチオマー分離のための方法
WO2011154496A1 (en) * 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
US8742103B2 (en) 2010-12-01 2014-06-03 Poxel Separation of triazine derivatives enantiomers using tartaric acid
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006984A1 (fr) * 2009-07-17 2011-01-20 Poxel Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
US20150246045A1 (en) * 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US20170266152A1 (en) * 2016-03-16 2017-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. LACHAUX 等: "Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy", 《CHRONIC HEART FAILURE》 *
邹仁通 等: "射血分数保留的心力衰竭新型药物研究进展", 《医学综述》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115770062A (zh) * 2021-09-07 2023-03-10 深圳迈瑞生物医疗电子股份有限公司 一种超声波数据的处理方法、成像装置
CN116440075A (zh) * 2023-06-01 2023-07-18 苏州中化药品工业有限公司 一种干混悬剂及其制备方法
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Also Published As

Publication number Publication date
WO2019069230A1 (en) 2019-04-11
CA3078163A1 (en) 2019-04-11
IL273723A (en) 2020-05-31
TW201924689A (zh) 2019-07-01
US11617754B2 (en) 2023-04-04
US20200316078A1 (en) 2020-10-08
MX2020003243A (es) 2020-09-18
JP2020536121A (ja) 2020-12-10
KR20200102982A (ko) 2020-09-01
EP3691650A1 (en) 2020-08-12
BR112020006472A2 (pt) 2020-10-06
ZA202002292B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
CN111163782A (zh) 治疗射血分数保留型心力衰竭的方法
TWI492745B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
Lang et al. The hemodynamic effects of dopamine in infants after corrective cardiac surgery
KR20130026504A (ko) 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
JP7444432B2 (ja) 心血管疾患を治療する方法
CN109069589A (zh) 用于心血管病况的司美鲁肽
JP2017128578A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
KIRKENDALL et al. Diagnosis and Treatment of Patients With Pheochromocytoma: Experiences at University Hospitals From 1941-1964
Stevens et al. Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
KR20200062240A (ko) 시포니모드의 투여 요법
US20140045947A1 (en) Methods for Maintaining or Improving Health, Well-Being and/or a Physiological Function in a Subject
HK40022791A (en) Methods of treating heart failure with preserved ejection fraction
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
TRIM et al. Renal effects of dopamine infusion in conscious horses
US20160067246A1 (en) Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
US20160184248A1 (en) Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
US12564615B2 (en) Treatment method for cardiac hypertrophy
Azza et al. Echocardiographic assessment of epicardial adipose tissue in obese children and its relation to clinical parameters of the metabolic syndrome
Limón-Bernal et al. Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat
WO2026063508A1 (ja) 医薬組成物
Kuang et al. Sacubitril/valsartan increased survival via inhibiting inflammation and myocardiofibrosis in Takotsubo-like cardiomyopathy
Mpharm et al. Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counter-regulation 2
Shen et al. Oral hypoglycemic agents
Lu et al. Report of 2 cases of glucagonoma syndrome with a brief review of literature

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40022791

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200515